Journal: BMC Immunology

Article Title: Comparative efficacy of glucocorticoid receptor agonists on Th2 cell function and attenuation by progesterone

doi: 10.1186/s12865-020-00383-8

Figure Lengend Snippet: A comparison of prednisolone- and dexamethasone-mediated reduction of type-2 cytokine mRNA levels in primary Th2 cells. Fold differences in mRNA level from corticosteroid (CS) treated cells compared to vehicle are provided ( n = 3). Quantification of IL-13 mRNA following steroid treatment ( a ). Comparison of CS ability to suppress IL-13 ( b ). The half maximal inhibitory concentration (IC 50 ) for prednisolone and dexamethasone required to suppress IL-13 mRNA expression ( c ). Quantification of IL-5 mRNA following CS treatment ( d ). Comparison of the ability of either CS to suppress IL-5 ( e ). A comparison of the IC 50 values for prednisolone and dexamethasone required to suppress IL-5 mRNA expression ( f ). Cell counts following culture in vehicle or increasing concentration of prednisolone or dexamethasone ( f ). Data represent mean and standard error. Pred, prednisolone; Dex, dexamethasone.* p < 0.05 determined by one-way ( a , d & g ) or two-way ( b & e ) RM ANOVA or t-test ( c & f )

Article Snippet: Fig. 4 Expression of the nuclear progesterone receptor (PGR) is undetectable in a Th2 cell line (CCRF-CEM) and primary Th2 cells, but present in a breast adenocarcinoma cell line (MCF-7) used as a positive control (n = 3; a ).

Techniques: Comparison, Concentration Assay, Expressing

Journal: BMC Immunology

Article Title: Comparative efficacy of glucocorticoid receptor agonists on Th2 cell function and attenuation by progesterone

doi: 10.1186/s12865-020-00383-8

Figure Lengend Snippet: A comparison of prednisolone- and dexamethasone-induced apoptosis in a Th2 cell line (CCRF-CEM). Data are expressed as percentage of 7AAD + cells ( a ) identifying dead cells. The half maximal dose (EC 50 ) for prednisolone and dexamethasone required to induce necrosis of cells ( b ). Percentage of Annexin V + 7AAD − cells, identifying apoptotic cells ( c ). A comparison of the EC 50 values for prednisolone and dexamethasone required to reach 50% maximal induction of apoptosis in cells ( d ; n = 11). Percentage of Annexin V + 7AAD − primary Th2 cells following treatment with dexamethasone, exhibiting a similar plateau effect as CCRF-CEM at 0.5 μM dexamethasone ( e ; n = 3). Comparison of CS-induced apoptosis in CCRF-CEM as fold-difference over vehicle ( f ). Data represent mean and standard error. Pred, prednisolone; Dex, dexamethasone. * p < 0.05 determined by two-way ( a & c ), t -test ( b & e ) or one-way RM ANOVA ( g )

Article Snippet: Fig. 4 Expression of the nuclear progesterone receptor (PGR) is undetectable in a Th2 cell line (CCRF-CEM) and primary Th2 cells, but present in a breast adenocarcinoma cell line (MCF-7) used as a positive control (n = 3; a ).

Techniques: Comparison

Journal: BMC Immunology

Article Title: Comparative efficacy of glucocorticoid receptor agonists on Th2 cell function and attenuation by progesterone

doi: 10.1186/s12865-020-00383-8

Figure Lengend Snippet: Corticosteroid-induced cell death is dampened by the female sex hormone progesterone. Dexamethasone-induced cell death ( a , % 7AAD + ) and apoptosis ( b , % Annexin V + 7AAD − ) of a Th2 cell line (CCRF-CEM) in the presence or absence of progesterone (2 μM, n = 5). Head-to-head comparison of apoptosis following treatment with prednisolone ( c ) or dexamethasone ( d ) with or without progesterone ( n = 4). The half maximal response (EC 50 ) for dexamethasone and prednisolone in the presence of progesterone ( e ). Influence of progesterone on the maximal response of prednisolone- or dexamethasone-induced apoptosis ( f ). Efficacy of prednisolone vs dexamethasone to induce apoptosis in the presence of prednisolone ( g ). Data represent mean and standard error. Pred, prednisolone; Dex, dexamethasone; Prog, progesterone; Pre, pretreatment. * p < 0.05 determined by one-way ( a - e ) or two-way ( f & g ) RM ANOVA

Article Snippet: Fig. 4 Expression of the nuclear progesterone receptor (PGR) is undetectable in a Th2 cell line (CCRF-CEM) and primary Th2 cells, but present in a breast adenocarcinoma cell line (MCF-7) used as a positive control (n = 3; a ).

Techniques: Comparison

Journal: BMC Immunology

Article Title: Comparative efficacy of glucocorticoid receptor agonists on Th2 cell function and attenuation by progesterone

doi: 10.1186/s12865-020-00383-8

Figure Lengend Snippet: Expression of the nuclear progesterone receptor (PGR) is undetectable in a Th2 cell line (CCRF-CEM) and primary Th2 cells, but present in a breast adenocarcinoma cell line (MCF-7) used as a positive control (n = 3; a ). Effect of progesterone with or without dexamethasone on expression of PIBF1 (n = 3, b ) . Progesterone reduced the dexamethasone-mediated increase in FKPB5 mRNA level, but had no effect when applied alone (n = 5, c ). Data represent mean and standard error. * p < 0.05 determined by one-way ANOVA

Article Snippet: Fig. 4 Expression of the nuclear progesterone receptor (PGR) is undetectable in a Th2 cell line (CCRF-CEM) and primary Th2 cells, but present in a breast adenocarcinoma cell line (MCF-7) used as a positive control (n = 3; a ).

Techniques: Expressing, Positive Control

Journal: BMC Immunology

Article Title: Comparative efficacy of glucocorticoid receptor agonists on Th2 cell function and attenuation by progesterone

doi: 10.1186/s12865-020-00383-8

Figure Lengend Snippet: RNA-sequencing of Th2 cells

Article Snippet: Fig. 4 Expression of the nuclear progesterone receptor (PGR) is undetectable in a Th2 cell line (CCRF-CEM) and primary Th2 cells, but present in a breast adenocarcinoma cell line (MCF-7) used as a positive control (n = 3; a ).

Techniques:

Journal: Cancers

Article Title: In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies

doi: 10.3390/cancers15010235

Figure Lengend Snippet: Overview of immunotherapeutic strategies and cell lines used in evaluation of their efficacy.

Article Snippet: Tafasitamab (anti-CD19 mAb) , B-ALL cell lines: SEM, Jurkat, CEM, MOLT-16, Nalm-6 cells , [ ] .

Techniques: Bioprocessing